Yale Department of Internal Medicine Celebrates Top Female Scientists
Last month, Research.com published the Best Female Scientists in 2022. The results were based on a ranking system which measures the impact of a researcher’s publications by combining the number of papers they have published and how often they are cited by other papers. 623 U.S.-based researchers appeared in list with three women representing the Yale Department of Internal Medicine.
Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial
No significant differences in targeted interventions occurred between patients with heart failure managed by clinicians with additional prognostic information compared to those without.Source: 2minutemedicine
Yale VAMOS Program Provides Holistic Vascular Care
The Vascular Medicine OutcomeS (VAMOS) program at Yale University, an integral program supported by the Yale New Haven Health’s Heart and Vascular Center and Center for Musculoskeletal Care, includes a global team of interventional cardiologists, vascular surgeons, podiatrists, radiologists, allied health professionals, and outcomes researchers committed to transforming how PAD is diagnosed and treated, and how patients access care.
Real-world outcomes study targets patients undergoing intravascular lithotripsy treatment at Yale
An observational study at the Heart and Vascular Center (HVC) at Yale New Haven Hospital (YNHH) Heart and Vascular Center could have major implications for patients with peripheral artery disease or PAD.
New Clinical Trial Evaluates Cardiovascular Outcomes in Tricuspid Valve Repair Without Open Heart Surgery
Investigators at the Yale School of Medicine are participating in an international study to evaluate the clinical outcomes of TriClip, the first non-surgical minimally invasive tricuspid valve repair device developed by Abbott.
Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy
A new analysis of the EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), found at 30 weeks improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) was greater in mavacamten patients than placebo.Source: DAIC
Outcomes Worse in Patients with Persistent Conduction Abnormalities after TAVR
Recent advances in TAVR have enabled lower-risk patients to benefit from this therapy. However, post-TAVR complications with the heart’s electrical impulses, known as conduction abnormalities, continue to undermine the next generation of valve repair devices.